Search

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Cancer Medicines Forum workshop April 5: a way forward for treatment optimization

The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

Read more

Nomination criteria

General criteriaOur refreshed EHA Awards program is designed to recognize and encourage the extraordinary achievements of individuals across the field of hematology. Eligibility
To nominate or be nominated, you must be an EHA member.

Read more

CAR NK-cells project, February 2025 update

A project update from Dr Ciprian Tomuleasa. We successfully designed and tested in vitro CAR T and CAR NK cells, transfected with the iCas9 suicide trigger.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more